The VSTM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VSTM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The VSTM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View VSTM Detailed Price Forecast - CNN Money||View VSTM Detailed Summary - Google Finance|
|View VSTM Detailed Summary - Yahoo! Finance||View VSTM Stock Research & Analysis - Zacks.com|
|View VSTM Trends & Analysis - Trade-Ideas||View VSTM Major Holders - Barrons|
|View VSTM Call Transcripts - NASDAQ||View VSTM Breaking News & Analysis - Seeking Alpha|
|View VSTM Annual Report - CompanySpotlight.com||View VSTM OTC Short Report - OTCShortReport.com|
|View VSTM Fundamentals - TradeKing||View VSTM SEC Filings - Bar Chart|
|View Historical Prices for VSTM - The WSJ||View Performance/Total Return for VSTM - Morningstar|
|View the Analyst Estimates for VSTM - MarketWatch||View the Earnings History for VSTM - CNBC|
|View the VSTM Earnings - StockMarketWatch||View VSTM Buy or Sell Recommendations - MacroAxis|
|View the VSTM Bullish Patterns - American Bulls||View VSTM Short Pain Metrics - ShortPainBot.com|
|View VSTM Stock Mentions - StockTwits||View VSTM Stock Mentions - PennyStockTweets|
|View VSTM Stock Mentions - Twitter||View VSTM Investment Forum News - Investor Hub|
|View VSTM Stock Mentions - Yahoo! Message Board||View VSTM Stock Mentions - Seeking Alpha|
|View Insider Transactions for VSTM - SECform4.com||View Insider Transactions for VSTM - Insider Cow|
|View VSTM Major Holdings Summary - CNBC||View Insider Disclosure for VSTM - OTC Markets|
|View Insider Transactions for VSTM - Yahoo! Finance||View Institutional Holdings for VSTM - NASDAQ|
|View VSTM Stock Insight & Charts - FinViz.com||View VSTM Investment Charts - StockCharts.com|
|View VSTM Stock Overview & Charts - BarChart||View VSTM User Generated Charts - Trading View|
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted on Wednesday December 05, 2018
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 83,978 shares of its common stock to four employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $5.21 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on December 3, 2018 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.
Verastem Oncology Presents Duvelisib Development Program Data at the American Society of Hematology 2018 Annual Meeting
Posted on Tuesday December 04, 2018
Multiple Clinical Data Presentations Highlighting Updated Long-Term Follow-Up from the Phase 3 DUO and the DUO Crossover Extension Studies
Verastem Oncology Announces Presentation of Updated Duvelisib Combination Clinical Data in Peripheral T-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
Posted on Monday December 03, 2018
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced an oral presentation highlighting new clinical data from an investigator sponsored trial, led by Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center (MSK), evaluating duvelisib in combination with romidepsin in patients with relapsed or refractory T-cell lymphomas, including peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) at the American Society of Hematology (ASH) 2018 Annual Meeting, taking place December 1-4, 2018, in San Diego. Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma.
New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production
Posted on Monday December 03, 2018
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.